-

CEO, Jakob Lindberg will present at BIO €quity Europe in Copenhagen May 10-11

Encouraging phase II data in multiple myeloma was presented at ASH annual meeting in December 2015, the poster can be downloaded here.

Oncopeptides is planning a pivotal phase III superiority study in late-stage multiple myeloma. The program includes 2 additional phase II studies and 1 additional phase I/II study. For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

Carnegie Healthcare Conference

-

47th Annual Meeting of the EBMT

-

The European Society for Blood and Marrow Transplantation 2021.

AACR Annual Meeting 2021

-

Virtual Meeting Week 1: April 10-15; Week 2: May 17-21

European School of Haematology E-conference 2021

-

E-Conference - How to Diagnose and Treat Multiple Myeloma.

COMy 2021

-

World Congress on Controversies in Multiple Myeloma 2021.

ASCO 2021 Annual Meeting

-

American Society of Clinical Oncology (ASCO) 2021.

EHA 2021 Virtual Congress

-

European Hematology Association Annual meeting 2021.

Interim Report Q2 2021

08:00 CET

Interim Report Q3 2021

08:00 CET